Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma

NCT03272256 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: IM156

Sponsor

ImmunoMet Therapeutics, Inc.